The mTOR kinase (mammalian Target of Rapamycin) is a major regulatory hub that senses and integrates nutrient, energy and growth factor inputs to promote cell growth. In this issue of EMBO Reports, Byun and colleagues report that high intracellular levels of lactate activate mTORC1 in KRAS transformed cells independently of a growth factor input [1]. This suggests a mechanism for how mTORC1 can be coopted to support oncogenic growth and proliferation.
despite the availability of oxygen. Lactate is the metabolic end product of glycolysis and is often dismissed as an unwanted byproduct that is discarded from the cell. However, recent studies have revealed an active role for lactate in cancer metabolism. There are several scenarios where tumor cells utilise lactate as a carbon source. For example, in the case of metabolic symbiosis, lactate generated in the inner, hypoxic core of a tumor is utilised by cells in the periphery of the tumor where oxygen levels are sufficient to support the back conversion of lactate to pyruvate for mitochondrial respiration. In the socalled reverse Warburg effect, non-transformed stromal cells are stimulated by tumor cells to produce lactate which is then taken up and utilised by tumor cells (reviewed in 2). There are also tumors where circulating lactate is taken up as a metabolic fuel [3] .
In this issue, Byun and colleagues report another interesting aspect of be inhibited by lactate [4] . Lactate administration has also been shown to activate mTORC1 in muscle of adult mice [5] .
What are the implications of this study? Lactate overproduction is seemingly more frequent in cancers than mTORC1 hyperactivation.
Presumably, there is a threshold for the concentration of intracellular lactate required for mTORC1 activation. Intracellular lactate is exported from cells by the ubiquitous MCT1 (monocarboxylate transporter) and by the hypoxiainduced MCT4 isoform whose expression is frequently induced in tumors.
Thus, depending on the levels of MCT1 and MCT4 expression, tumors differ in their lactate exporting capacity and thereby in their ability to accumulate intracellular lactate to levels required for mTORC1 activation. Few data are available on intracellular lactate concentrations in tumors to confirm this assumption. Nevertheless, as an MCT1 inhibitor (AZD3965) is currently in clinical trials for cancer [6] , it would be of interest to ascertain if high intracellular lactate levels may have the undesired effect of stimulating mTORC1 in patient tumors.
Conversely, mTORC1 activation is encountered in cancers where none of its negative regulators (TSC and PTEN) are mutated. These negative regulators are upstream of Rheb. In these cases, it is possible that mTORC1 is activated by lactate blocking TSC action. Again, this can be addressed by determining the intracellular lactate concentration in tumors.
Are there normal physiological conditions where lactate could serve as an mTORC1 activator? Upon stimulation, T-cells go through a short phase of rapid proliferation. As in cancer, this rapid proliferation is characterized by a shift to aerobic glycolysis to generate ATP and biosynthetic precursors for formation of new cells. The increase in glycolysis could also serve to produce lactate to sustain mTORC1 activation. Indeed, T-cell activation is exquisitely sensitive to rapamycin (IC50 ~0.05nM, substantially below that required in other cells) [7] , suggesting that maintaining mTORC1 activity is critically important in T-cell activation. However, it should be noted that T-cell proliferation is blocked by MCT1 inhibition (which should result in even higher intracellular lactate levels and mTORC1 activation) [8] .
Lactate is receiving belated recognition as being more than an unwanted end-product of glycolysis. It is also a source of metabolic fuel and a signaling molecule in its own right [9] . The central finding of this study, namely that lactate activates mTORC1, has important implications for cancer biology and beyond. 
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